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ABSTRACT 43 
Objective: To ascertain the prevalence of erectile dysfunction (ED), how it is perceived 44 
and the percentage seeking treatment for the condition in a population of men with 45 
cardiovascular disease (CVD) attending a cardiac rehabilitation programme in East 46 
London, United Kingdom (UK).  47 
Participants: 100 male participants aged between 30 and 88 years attending a cardiac 48 
rehabilitation centre in East London. 49 
Methods: An audit of men attending a cardiac rehabilitation programme was 50 
conducted. Participants completed the International Index of Erectile Function (IIEF-5) 51 
to ascertain the severity of ED; adapted Ǯbother scoreǯ item from the International 52 
Prostate Symptom Score (IPSS) to investigate the extent to which participants were 53 
bothered by the symptoms of their ED and questions related to both ED treatment-54 
seeking and beliefs about the impact of cardiac medication on ED. Demographic and 55 
clinical data were also collected. The audit was carried out between January and 56 
September 2014. 57 
Results: Out of 117 male participants, 100 were audited (85.5% uptake). Prevalence of 58 
ED in this cohort was 80% and 38% were suffering with moderate or severe ED. Older 59 
men had significantly higher levels of ED and participants with severe ED were 60 
significantly more bothered by their condition. Those of Asian or British Asian descent 61 
reported significantly higher levels of ED severity than men from white ethnic 62 
backgrounds. 65% of men with ED had never spoken to a healthcare professional (HCP) 63 
about the condition and 35% believed that their medication had a deleterious effect on 64 
erectile function.  65 
Conclusion: High incidences of ED remain undetected in this patient population. The 66 
study stresses the importance for HCPs to discuss ED with patients within primary care 67 
and cardiac rehabilitation programmes, which in turn could reduce mortality in those at 68 
risk of a future cardiac event, as well as facilitate access to ED treatment.  69 
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 95 
INTRODUCTION 96 
The term cardiovascular disease (CVD) refers to all diseases of the heart and circulatory 97 
system and costs the NHS and the United Kingdom (UK) economy approximately £30.6 98 
billion per year (Care Quality Commission. 2014) Coronary heart disease (CHD) is one 99 
such disease and is the biggest single cause of death in the UK. For men, CHD is the most 100 
common cause of premature death (mortality before 75 years of age) and was 101 
responsible for over 15% (>17,000) of premature deaths in 2012 (Bhatnagar et al. 102 
2015). 103 
 104 
Erectile dysfunction (ED) is defined as a manǯs consistent or recurrent inability to attain 105 
and/or maintain a penile erection sufficient for sexual activity (Montorsi et al. 2010). 106 
Prevalence rates of ED for individuals at risk of, or suffering with CVD are reported to be 107 
as high as 75% (British Heart Foundation 2014;Dusing 2003). ED and CVD share similar 108 
aetiologies and risk factors including; obesity, diabetes mellitus, physical inactivity, 109 
hypertension, dyslipidaemia and tobacco usage (Ponholzer et al. 2005). ED is typically 110 
experienced before the onset of a cardiac event and can be regarded as an early 111 
indication of underlying CVD (Montorsi et al. 2003). Due to arteries in the penis being 112 
approximately 1 – 2 mm compared to larger arteries such as coronary arteries (3 – 4 113 
mm), they suffer obstruction by atheromatous plaque earlier (Jackson 2013). Therefore, 114 
early diagnosis of ED can be a crucial indication of undetected CVD. The mean time 115 
between developing ED and having a cardiovascular event, such as myocardial 116 
infarction or cerebrovascular accident, is approximately three years (Montorsi et al. 117 
2003).  118 
  119 
Medication prescribed for CVD can cause further deleterious effects in relation to 120 
erectile function (Nicolai et al. 2014). Side-effects of antihypertensive medications 121 
(particularly beta-blockers and thiazide diuretics) can cause ED (Dusing 2005). As a 122 
result, patients who experience ED as a side-effect can become non-adherent to such 123 
medication regimes (Doumas and Douma 2006). In a qualitative study involving a 124 
cohort of 38 hypertensive patients, ED was reported as a reason for missing doses or for 125 
ceasing hypertensive medication to preserve erectile function, however, the authors do 126 
not report which hypertensive medications patients were taking (Voils et al. 2008). A 127 
recent systematic review provides support for the notion that both thiazide diuretics 128 
and a majority of beta-blockers have a negative effect on erectile function, whilst the 129 
beta-blocker Nebivolol, may have a positive effect. It is suggested that this is due to 130 
nitric oxide-mediated vasodilatory properties, which improve endothelial function and 131 
hence erectile function. In addition, it was concluded that there was no evidence to 132 
suggest that; angiotensin-converting-enzyme (ACE) inhibitors, angiotensin-receptor-133 
blockers ȋARBǯsȌ and calcium-channel-blockers have a deleterious effect on erectile 134 
function (Baumhakel et al. 2011). 135 
 136 
In addition to pharmacological induced ED, patient perceptions are important when 137 
considering the effects of CVD medication on ED. Ninety-six men prescribed atenolol for 138 
CVD were split up into 3 groups; one group were blinded to the drug given, the second 139 
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were informed about the drug but not its side effects and the final group were informed 140 
about the drug and its side effects, which included ED (Silvestri et al. 2003). ED was 141 
reported in 3.1, 15.6 and 31.2% of the groups respectively. It was suggested that 142 
knowledge and beliefs about the potential side effects of CVD medication may create 143 
anxiety, which in turn, may have an effect on erectile function (Silvestri et al. 2003). An 144 
alternative explanation could be that an awareness of the link between CVD medication 145 
and ED may increase the reporting of erectile symptoms.   146 
 147 
The International Prostate Symptom Score questionnaire (IPSS) includes an item which 148 
is referred to as the Ǯbother scoreǯ. This item has previously been adapted and used in 149 
ED research (Steggall and Butler 2012). Steggall and Butler (2012) indicated that 150 
regardless of ED severity, men who took part in their study were Ǯbotheredǯ by their 151 
condition and perceived their symptoms negatively. Despite this, help-seeking in 152 
relation to ED is problematic. Research indicates that less than 25% of men actively 153 
seek treatment for ED (Laumann et al. 2009) and embarrassment is often reported as a 154 
major reason for not wanting to discuss sexual health issues with a healthcare 155 
professionals (HCP) (Byrne et al. 2013). Hackett recommends that in order to improve 156 
detection, patients presenting in primary care with diabetes, obesity, depression or 157 
cardiovascular disease should be asked whether they are experiencing ED (Hackett 158 
2009).  159 
 160 
This paper details an audit of a cardiac rehabilitation service in East London to ascertain 161 
the prevalence of ED and whether it has been detected and/or treated. The audit aimed 162 
to: 163 
- investigate the prevalence and severity of ED in a cohort of men attending a 164 
community based cardiac rehabilitation service in East London using the 165 
International Index for Erectile Function (IIEF-5) (Rosen et al. 1999) 166 
- identify the extent to which patients are bothered by their ED  167 
- identify what proportion of men with ED had sought treatment 168 
- identify whether men considered ED to be a side-effect of medication  169 
METHODS 170 
Participants 171 
All men attending the cardiac rehabilitation programme were eligible for inclusion in 172 
the audit.  173 
 174 
Procedure  175 
Permission to conduct the audit was obtained from the Assurance Department of East 176 
London NHS Foundation Trust (ELFT) and subsequently took place between January 177 
and September 2014. ELFT provides a cardiac rehabilitation programme across a 178 
variety of locations including both community and hospital based settings in East 179 
London. Men who were newly referred to the cardiac rehabilitation programme were 180 
given the audit questionnaire to complete when they arrived to participate in one of the 181 
cardiac rehabilitation sessions. Participants were informed that all questionnaire 182 
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responses would be anonymous. In accordance with the Data Protection Act 1998 183 
(Parliament 1998) all aspects of participantsǯ data were treated with strict confidence. 184 
Each participant was assigned a unique identification number to ensure data were 185 
anonymised. Hard copies of questionnaires were stored within locked filing cabinets in 186 
a locked office on NHS premises, along with digital data which were stored on an NHS 187 
password protected network drive. 188 
 189 
Materials 190 
As part of standard care, participants completed a self-report questionnaire. Clinical and 191 demographic data were extracted from participantsǯ medical records. Where 192 
participants could not speak English, a member of the Trusts health advocacy service 193 translated the questions and recorded participantsǯ responses. The pack included the 194 
IIEF-5; a self-report questionnaire designed to detect the presence and severity of ED 195 
(Rosen et al. 1999). It has been utilised successfully across a wide variety of studies, 196 
translated into more than 30 languages and used extensively throughout the world 197 
(Cappelleri and Rosen 2005). Each item of the IIEF-5 is scored on a five-point Likert 198 
scale from; Ǯ1ǯ least functional, to; Ǯͷǯ most functional. Possible overall scores range from 199 
1 to 25; 21 and above is considered to indicate normal erectile function. Conversely, 200 
lower overall scores represent poorer sexual function (See appendix; table 1) (Rhoden 201 
et al. 2002). 202 
 203 
The Ǯbotherǯ question from the IPSS was re-worded for use with ED; ‘If you were to 204 
spend the rest of your life with your erectile function just the way it is now, how would 205 
you feel about that?ǯ Using a Likert scale, a score of 0 indicated being Ǯdelightedǯ, 1 206 Ǯpleasedǯ, 2 Ǯmostly satisfiedǯ, 3 Ǯmixedǯ, 4 Ǯmostly dissatisfiedǯ, 5 Ǯunhappyǯ and 6 207 Ǯterrible.ǯ This item has been used in men with ED (Steggall & Butler 2012) and is 208 
considered both valid and reliable (O'Leary 2005).  209 
 210 
The audit also included the questions; ǮDo you think any of your medications affect your 211 erectile function?ǯ and Ǯ(ave you ever told your doctor or nurse about your erectile 212 
problems?ǯ where participants answered either ǮYesǯ or ǮNoǯ.  213 
 214 
Statistical Analysis   215 
Data were analysed using IBM SPSS Statistics 21. To investigate the prevalence of ED, 216 
descriptive statistics were used for participant demographics and clinical data. Analysis 217 
of variance (ANOVA) and analysis of covariance (ANCOVA) were used to investigate 218 
differences between the five categories of ED severity on age and the subsequent degree 219 
of bother, as well as differences in ED severity in relation to ethnicity. 220 
 221 
RESULTS 222 
Demographic characteristics 223 
Of the 117 men approached, 100 (85.5%) completed the audit. Participants who refused 224 
were widowed (n=2, 1.7%); had a wife who was not living in the country (n=3, 2.6%); 225 
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did not complete the questionnaire or did not wish to participate (n=12, 10.25%). Ages 226 
ranged between 30 and 88 years with a mean age of 56.82 years (SD=10.48). A majority 227 
of the men were married (77%) and were non-smokers (72%). Patients were mainly 228 
Asian or British Asian i.e. Indian, Pakistani or Bangladeshi (n= 49, 49%) (See appendix; 229 
table 2). 230 
 231 
Clinical characteristics 232 
The majority of participants were attending cardiac rehabilitation as a result of a 233 
myocardial infarction (41%) or angina (31%). The most commonly prescribed 234 
medications were aspirin (97%) and statins (92%). The most prevalent comorbidities 235 
were hypertension (50.5%), hypercholesterolemia (48%) and type 2 diabetes (30%) 236 
(See appendix; table 3).   237 
ED prevalence, severity and age  238 
Of the 100 men who completed the IIEF-5, 80 (80%) suffered some degree of ED. The 239 
self-reported mean duration of ED was 2.8 years (SD= 3.32 years) and the mean IIEF-5 240 
score was 14.91 (SD= 6.5) (See appendix; table 4).  241 
  242 
Moderate or severe ED was reported by 38 (38%) of men. An ANOVA indicated a 243 
significant difference in age between the five categorisations of ED severity; F (4, 95) = 244 
6.59, p= 0.0001, partial eta squared = 0.22. The post hoc Tukey HSD test indicated that 245 
those with severe ED were significantly older than those with mild to moderate, mild 246 
and no ED (See appendix; table 5). 247 
 248 
Bother score 249 
Using the IPSS bother question to ascertain how participants felt about spending the 250 
rest of their lives with their current erectile function revealed that; 11 participants 251 
(11%) felt Ǯdelightedǯ, ͳͷ participants ȋͳͷ%Ȍ were Ǯpleasedǯ, ͳ ȋͳ%Ȍ was Ǯmostly 252 satisfiedǯ, ʹ͸ ȋʹ͸%Ȍ had Ǯmixedǯ feelings, ͳ8 ȋͳ8%Ȍ felt Ǯmostly dissatisfiedǯ or Ǯunhappyǯ 253 
(n=18, 18%) and 8 men ȋ8%Ȍ reported that they felt Ǯterribleǯ.   254 
 255 
An ANCOVA was used to explore differences between the 5 categorisations of ED 256 
severity and bother whilst controlling for the effects of age (See appendix; table 5). 257 
Results revealed a significant difference between groups on levels of bother F (4, 91) = 258 
18.59, p < 0.01, partial eta squared = 0.45. Pairwise comparisons indicated that those 259 
with severe ED were significantly more bothered by their symptoms than those with all 260 
other ED severities including those with no ED. Those with mild, mild to moderate and 261 
mild ED were significantly more bothered by their symptoms than those with no ED.  262 
 263 
Ethnic background was looked at in relation to ED severity (See appendix; table 6). ED 264 
severity was treated as a continuous variable as there were too few observations within 265 
some cells to perform a chi-squared test. An ANCOVA was utilized to look for any 266 
significant differences between ethnic groups in relation ED, whilst controlling for age. 267 
A significant difference existed between groups; F (3, 95) = 4.22, p = .008, partial eta 268 
squared = .117. Pairwise comparisons indicated that Asian or British Asian men scored 269 
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significantly lower on the IIEF-5 than those from white ethnic backgrounds, therefore, 270 
men of Asian or British Asian descent reported significantly higher levels of ED severity 271 
than white men.   272 
 273 
ED severity and comorbidities  274 
Of the 100 men who took part in the audit, 50 (50%) had hypertension, 30 (30%) had 275 
type II diabetes and 19 (19%) had both conditions (See appendix; table 7). Almost all 276 
men with diabetes had ED (29/30, 96.7%) and 80% had moderate or severe ED. In men 277 
with hypertension; 86% had ED and 46% had moderate to severe ED. All men with both 278 
diabetes and hypertension had at least mild ED and 84% had moderate or severe ED.  279 
 280 
Treatment seeking 281 
Of the 80 men with ED, 52 (65%) had never spoken to a HCP about their condition. Of 282 
those with moderate or severe ED, 52.6% had spoken to a HCP, while in those with less 283 
severe ED i.e. mild or mild to moderate severity; only 14.3% had done so. Of these men 284 
only one individual was receiving treatment for ED. Thirty five percent of men 285 
diagnosed with ED believed that medication was having an effect on their erectile 286 
function.  287 
DISCUSSION 288 
The prevalence of ED in this cohort of men attending a cardiac rehabilitation 289 
programme was 80%, which is similar to that found in previous research (British Heart 290 
Foundation 2014;Dusing 2003). Men with severe ED were significantly older and more 291 
bothered by their symptoms.  However, even those with mild ED reported feeling either 292 
mostly Ǯdissatisfiedǯ or Ǯterribleǯ about their erectile function, echoing the results of 293 Steggall and Butlerǯs (2012) research which found that men with heart failure, 294 
regardless of the severity of their ED, were bothered by the condition . The majority of 295 
participants were Asian or British Asian, reflecting the composition of the local 296 
community and these men were experiencing significantly more severe ED than men 297 
from white ethnic backgrounds. The scope of this audit was not broad enough to 298 
suggest reasons for this; therefore further research focussing on differences between 299 
ethnic groups in relation to ED is needed. 300 
 301 
Both ED and CVD share similar aetiologies and risk factors, including diabetes mellitus 302 
and hypertension (Ponholzer et al. 2005). The mean duration of ED in this cohort of 303 
men was 2.8 years, echoing the findings of Montorsi et al. (2003) who suggest that the 304 
mean time between developing ED and experiencing a cardiovascular event is 305 
approximately 3 years. In addition, this audit confirmed that men who were living with 306 
comorbid hypertension or type II diabetes were likely to report higher levels of ED 307 
severity.  308 
 309 
A large proportion of men were prescribed beta-blockers, which have been reported as 310 
having negative effects on erectile function (Baumhakel et al. 2011;Nicolai et al. 2014). 311 
Approximately one third of men believed that their medication impacted on their 312 
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erectile function. It is however, unclear whether it is the drugs themselves that may be 313 
causing this effect or beliefs and expectations men have about possible side effects, as 314 
demonstrated by Silvestri et al. (2003). Future research could address this important 315 
question by investigating menǯs beliefs about their CVD treatment in relation to ED, in 316 
order to examine whether such beliefs influence menǯs adherence to cardiac medication.  317 
 318 
Despite 80% of the sample suffering with ED, 65% had not discussed their condition 319 
with a HCP, reflecting the findings of Laumann et al. (2009) who suggest that less than 320 
25% of men seek help for ED. Byrne et al 2013 suggests that this is due to 321 
embarrassment with regard to discussing sexual health issues with HCPs. A limitation of 322 
this audit resides in the potentially embarrassing nature of ED and the format in which 323 
participants completed the questionnaire. Cardiac rehabilitation classes are group 324 
based. With this in mind, all efforts were made to safeguard participantǯs privacy when 325 
completing the questionnaire; however, it is unlikely that feelings of embarrassment 326 
were completely eliminated. This could have been exacerbated in the small number of 327 
participants that did not speak English who were read the questions aloud by a health 328 
advocate. Although people who do not speak English are likely to have experience of 329 
discussing their health with a health advocate, it would be prudent to keep this in mind 330 
when considering the results to this audit.   331 
 332 
The present audit, in line with previous research, highlights the important link between 333 
CVD, diabetes, hypertension and comorbid ED (Ponholzer et al. 2005). Patients 334 
presenting with such diseases offer an opportunity to enquire about and screen for ED. 335 
Hackett (2009) suggests that HCPs need to assess ED effectively by asking the right 336 
questions and demonstrate a willingness to take ED seriously as a medical condition. 337 
The results of this audit suggest that this is still a serious obstacle preventing patients 338 
obtaining necessary medical help. It highlights the need for ED to be adequately 339 
addressed and screened for in order to detect CVD early and facilitate access to ED 340 
treatment. This could be achieved in primary care, but is also true of cardiology clinics 341 
and cardiac rehabilitation programmes. If the profile of ED can be raised and the topic 342 
addressed in various healthcare settings, then the possibility exists to reduce mortality 343 
in those at risk of a future cardiac event, as well as increase quality of life in those 344 
suffering with ED.     345 
 346 
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 What is already known about this subject? 
 Cardiovascular disease (CVD) and erectile dysfunction (ED) share similar risk 
factors and aetiologies. It is estimated that the average time between first 
experiencing ED and suffering a cardiac event is approximately 3 years. As a result, 
ED is seen as an important early indication of CVD. Many men do not seek treatment 
for ED.  
 
 What does this study add? 
 Although the link between ED and CVD has been known for several years, this study 
found that ED is still going undiagnosed. Of those with moderate to severe ED 
symptoms, over half had not spoken to a HCP about their ED. Over one third of men 
with ED symptoms believed that their medication affected their erectile function. If 
HCPs ask men who are known to be at risk of or have CVD about erectile function, it 
could have important consequences for identifying CVD early as well as facilitating 
access to ED treatment. 
 
 358 
 359 
 360 
 361 
 362 
 363 
 364 
 365 
 366 
 367 
 368 
 369 
 370 
  371 
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Appendix 450 
Table 1: IIEF-5 points threshold 451 
Threshold  Diagnosis 
>21 Normal Erectile Function 
17 – 21 Mild Erectile Dysfunction 
12 – 16 Mild to Moderate Erectile 
Dysfunction 
8 – 11 Moderate Erectile Dysfunction 
1 – 7 Severe Erectile Dysfunction 
 452 
Table 2: Participant Demographics 453 
Characteristic Respondents N (%) 
Age:  ≤ ͵Ͳ 1 (1) 
31 - 40 7 (7) 
41 - 50 13 (13) 
51 - 60 49 (49) 
> 60 30 (30) 
Total 100 (100) 
Ethnicity:  
White British 25 (25) 
White Irish 5 (5) 
Any other white background 4 (4) 
Asian or Asian British Indian 16 (16) 
Asian or Asian British 
Pakistani 
15 (15) 
Asian or Asian British 
Bangladeshi 
18 (18) 
Any other Asian background 9 (9) 
Black or Black British 
Caribbean 
1 (1) 
Black or black British 1 (1) 
Any other black background 1 (1) 
Chinese 1 (1) 
Any other ethnic background 4 (4) 
Total 100 (100) 
Relationship Status:  
Single 9 (9) 
Married 77 (77) 
Partner 6 (6) 
Divorced 2 (2) 
Separated 1 (1) 
Total 95 (95) 
Smoking Status:  
Smoker 13 (13) 
Non-Smoker 72 (72) 
Ex-Smoker 15 (15) 
Total 100 (100) 
13 
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Table 3: Participant Clinical Data  456 
 457 
Characteristic Respondents N (%) 
History of CVD Diagnoses:  
Myocardial infarction 41 (41) 
Coronary artery disease 24 (24) 
Angina 31 (31) 
Heart failure   4 (4) 
Dilated cardiomyopathy   1 (1) 
Ischemic heart disease   7 (7) 
Heart valve disease   5 (5) 
Arterial fibrillation   4 (4) 
CVD Medication:  
Aspirin / Second anti-platelet / 
Anticoagulants  
97 (97) 
ACE Inhibitor / Angiotensin II 
antagonist 
84 (84) 
Beta Blocker 81 (81) 
Statin 92 (92) 
Glyceryl Trinitrate (GTN) spray 65 (65) 
Calcium Channel Blocker 18 (18) 
Potassium channel activator 5 (5) 
Diuretics 24 (24) 
Anti-arrhythmia drugs 2 (2) 
Comorbidities:  
Hypertension 50 (50) 
Type 2 diabetes 30 (30) 
Hypercholesterolemia 48 (48) 
 458 
 459 
 460 
 461 
 462 
 463 
 464 
 465 
 466 
 467 
 468 
 469 
 470 
 471 
 472 
 473 
 474 
 475 
 476 
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Table 4: Participant responses by item on the IIEF-5, n(%) 477 
 478 
How do you rate your 
confidence that you 
could get and keep an 
erection? 
Very 
Low 
Low Moderate High Very 
High 
Total 
20(20) 20(20) 28(28) 22(22) 10(10) 100 
(100) 
When you had 
erections with sexual 
stimulation, how often 
were your erections 
hard enough for 
penetration? 
 
Almost 
never/
never 
A few times 
(much less 
than half 
the time) 
Sometimes 
(about half 
the time) 
Most 
times 
(much 
more 
than half 
the time) 
Almost 
always/
always 
 
23(23) 23(23) 18 (18) 17(17) 19(19) 100 
(100) 
During sexual 
intercourse, how often 
were you able to 
maintain your erection 
after you had 
penetrated (entered) 
your partner? 
 
Almost 
never/
never 
A few times 
(much less 
than half 
the time) 
Sometimes 
(about half 
the time) 
Most 
times 
(much 
more 
than half 
the time) 
Almost 
always/
always 
 
21(21) 23(23) 19(19) 19(19) 18(18) 100 
(100) 
During sexual 
intercourse, how 
difficult was it to 
maintain your erection 
to completion of sexual 
intercourse? 
 
Extrem
ely 
Difficul
t 
Very 
difficult 
Difficult Slightly 
difficult 
Not 
difficult 
 
17(17) 19(19) 14(14) 21(21) 29(29) 100 
(100) 
When you attempted 
sexual intercourse, how 
often was it satisfactory 
for you? 
 
Almost 
never/
never 
A few times 
(much less 
than half 
the time) 
Sometimes 
(about half 
the time) 
Most 
times 
(much 
more 
than half 
the time) 
Almost 
always/
always 
 
21(21) 17(17) 19(19) 20(20) 23(23) 100 
(100) 
 479 
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Table 5: Participants IIEF scores in relation to the bother score  491 
 492 
ED and bother score as Indicated by IIEF-5 and IPSS Bother 
Question 
 
n(%) 
Bother 
score (IPSS 
item) 
M(SD) 
Age 
M(SD) 
Severe ED  19 (19) 4.74 (1.28) 64.70 (10.86) 
Moderate ED  19 (19)   3.50 (1.42) 59.63 (7.23) 
Mild/Moderate ED  17 (17) 3.59 (1.18) 55.47 (8.72) 
Mild ED  25 (25) 2.79 (1.53) 54.96 (9.69) 
No ED  20 (20) 1.26 (1.76) 50.10 (10.21) 
Total 100 (100)   
 493 
Table 6: Ethnic group and ED severity 494 
 495 
Ethnicity Severe 
ED 
n (%) 
Moderate 
ED 
n (%) 
Mild/Moderate 
ED 
n (%) 
Mild ED 
n (%) 
No ED 
n (%) 
Total 
n (%) 
White English 4 (21) 3 (15.8) 3 (17.6) 7 (28) 8 (40) 25 (25) 
White Irish 1 (5.3) 1 (5.3) 0 2 (8) 1 (5) 5 (5) 
Other white 
background 
0 0 1 (5.9) 0 3 (15) 4 (4) 
Black or black British 0 0 0 0 1 (5) 1 (1) 
Black or black British 
Caribbean 
0 1 (5.3) 0 0 0 1 (1) 
Any other black 
background 
0 0 0 0 1 (5) 1 (1) 
Asian or Asian British 
Indian 
5 (26.3) 0 4 (23.5) 5 (20) 2 (10) 16 (16) 
Asian or Asian British 
Pakistani 
4 (21) 2 (10.5) 5 (29.4) 3 (12) 1 (5) 15 (15) 
Asian or Asian British 
Bangladeshi 
3 (15.7) 6 (31.6) 3 (17.6) 4 (16) 2 (10) 18 (18) 
Any other Asian 
background 
1 (5.3) 4 (21.1) 1 (5.9) 3 (12) 0 9 (9) 
Chinese 1 (5.3) 0 0 0 0 1 (1) 
Any other ethnic 
background 
0 2 (10.5) 0 1 (4) 1 (5) 4 (4) 
Total 19 (19) 19 (19) 17 (17) 25 (25) 20 (20) 100 
(100) 
 496 
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Table 7: ED severity, type II diabetes and hypertension 503 
 504 
 Total number 
of participants 
by category 
n (%) 
Participants 
with type II 
diabetes 
mellitus  
n (%) 
 
Participants 
with 
hypertension  
n (%) 
 
Participants 
with both 
hypertension 
and type II 
diabetes 
mellitus n (%) 
Severe ED  19 (19) 13 (43.4) 14 (28) 11 (57.9) 
Moderate ED  19 (19) 11 (36.7)   9 (18) 5 (26.3) 
Mild/Moderate ED  17 (17) 2 (6.6)    9 (18) 1 (5.3) 
Mild ED  25 (25) 3 (10) 11 (22) 2 (10.5) 
No ED  20 (20) 1 (3.3) 7 (14) 0(0) 
Totals 100 (100) 30 (100) 50 (100) 19 (100) 
 505 
 506 
